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Fanconi anemia (FA) is a genetic disorder character-
ized by bone marrow failure, congenital abnormalities,
cancer susceptibility, and a marked cellular hypersen-
sitivity to DNA interstrand cross-linking agents, which
correlates with a defect in ability to repair this type of
damage. We have previously identified an approxi-
mately 230-kDa protein present in a nuclear protein
complex in normal human lymphoblastoid cells that is
involved in repair of DNA interstrand cross-links and
shows reduced levels in FA-A cell nuclei. The FANCA
gene appears to play a role in the stability or expression
of this protein. We now show that p230 is a well known
structural protein, human a spectrin II (aSpIIS*), and
that levels of aSpIIS* are not only significantly reduced
in FA-A cells but also in FA-B, FA-C and FA-D cells (i.e. in
all FA cell lines tested), suggesting a role for these FA
proteins in the stability or expression of aSpIIS*. These
studies also show that aSpIIS* forms a complex in the
nucleus with the FANCA and FANCC proteins. aSpIIS*
may thus act as a scaffold to align or enhance interac-
tions between FA proteins and proteins involved in DNA
repair. These results suggest that FA represents a disor-
der in which there is a deficiency in aSpIIS*.
Fanconi anemia (FA)1 is a recessively transmitted genetic
disorder characterized by bone marrow failure, diverse congen-
ital abnormalities, and an increased incidence of cancer (1–3).
One of the distinguishing characteristics of this disease is the
marked cellular hypersensitivity to interstrand cross-linking
agents, which correlates with a defect in ability to repair dam-
age produced by these agents (3–7). The etiopathogenesis of FA
remains unclear, however, despite the fact that genes for three
of its eight known complementation groups (FANCA, FANCC,
and FANCG) have been cloned and their protein products ex-
amined (8–11). How the DNA repair defect is related to the FA
genes or gene products or to the clinical manifestations of the
disorder is unclear.
We have isolated a chromatin-associated protein complex
from the nuclei of normal human lymphoblastoid cell nuclei
and have shown that this complex is involved in the repair of
DNA interstrand cross-links (12–15). A number of the proteins
involved in nucleotide excision repair are present in this com-
plex (16). In FA-A and FA-D cells there is a defect in the ability
of this complex to incise DNA containing interstrand cross-
links (13, 14). We have recently shown that there is a deficiency
in FA-A cells in the levels of an approximately 230-kDa protein
present in this nuclear complex and that the FANCA gene
plays a role in the stability or expression of this protein (16).
We have now determined the identity of the 230-kDa protein
and shown that it is the structural protein a spectrin II
(aSpIIS*). We have also shown that levels of aSpIIS* are
significantly reduced in FA-B, FA-C, and FA-D, as well as FA-A
cells and that this protein forms a complex in the nucleus with
the FANCA and FANCC proteins. Thus aSpIIS* may act as a
scaffold to align or enhance interactions between the FA pro-
teins and other proteins in the nucleus such as those involved
in DNA repair. Because nonerythroid a spectrin has been
shown to interact with proteins involved in a number of cellular
processes, such as DNA synthesis, cell cycle progression, gene
expression, signal transduction, and cell growth and differen-
tiation (17–22), a deficiency in this protein in FA cells could
have far reaching consequences due to the number of systems
affected. This may explain some of the diverse cellular and
clinical defects that have been reported in FA (1–3).
EXPERIMENTAL PROCEDURES
Chromatin-associated Protein Extracts—Normal human (GM 1989
and GM 3299) lymphoblastoid cell lines were obtained from the Coriell
Institute for Medical Research, Camden, NJ. FA-A (HSC 72 and HSC
99), FA-B (HSC 230), FA-C (HSC 536), and FA-D (HSC 62) lymphoblas-
toid cell lines were a gift from Dr. Manuel Buchwald (Hospital for Sick
Children, Toronto, Canada). FA-A lymphoblastoid cells (HSC 72) were
stably transduced with a retroviral vector expressing the FANCA cDNA
(HSC 72–17) (23). Cell lines were grown in suspension culture in RPMI
1640 medium as described previously and routinely checked for myco-
plasma using an American Type Culture Collection polymerase chain
reaction-based mycoplasm detection kit (13). HeLa cells were obtained
from Cellex Biosciences, Inc., Minneapolis, MN. Cell nuclei were iso-
lated, and the chromatin-associated proteins were extracted from them
in a series of steps as described previously (13, 24).
Development and Purification of Monoclonal antibodies (mAb)—
mAbs were developed, as described previously, against proteins in the
endonuclease complex, pI 4.6, which was isolated from chromatin-
associated proteins in the nuclei of normal human lymphoblastoid cells
and recognizes and incises DNA containing interstrand cross-links (12,
16). One of the mAbs developed was against the 230-kDa protein. This
mAb, which completely inhibited activity of the protein complex on
DNA containing interstrand cross-links produced by 8-methoxypsor-
alen plus UVA light, was of the IgM class; it was subsequently purified
on a Superose 6HR 10/30 size exclusion column (Amersham Pharmacia
Biotech).
Identification of the 230-kDa Protein—HeLa chromatin-associated
proteins were separated by SDS-PAGE on a 7–9.5% gradient gel (15 3
20-cm). After separation, a portion of the gel was cut off and electro-
blotted onto a nitrocellulose membrane. One-half of the membrane was
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stained with colloidal gold (Bio-Rad), and the other half was immuno-
blotted with anti-p230. In this way the 230-kDa band could be identified
on the stained membrane. The remainder of the gel was stained with
Coomassie, and the 230-kDa band was identified, excised, and sent to
the HHMI Biopolymer Facility/W. M. Keck Foundation Biotechnology
Resource Laboratory at Yale University for mass spectrometric analysis
by matrix-assisted laser desorption ionization mass spectrometry
(MALDI-MS).
At the Keck Facility, the protein was digested within the gel slice
with trypsin. The resulting digest was mixed with a-cyano-4-hydroxy
cinnamic acid matrix solution and spotted onto a sample target (25).
The sample target was then introduced into the mass spectrometer, a
Micromass TofSpec S.E. that can be used in either the linear or reflec-
tron mode and is equipped with delayed extraction, which increases
resolution and mass accuracy. The resulting peptide masses were then
subjected to peptide mass searching using Peptide Search and Profound
to identify proteins whose sequences were in the EMBL nonredundant
and OWL data bases, respectively.
Staining of Electrophoretically Separated HeLa Cell Proteins—To get
a better idea of the relative abundance of the 230-kDa protein in the
HeLa cell chromatin-associated protein extracts, these extracts were
separated by SDS-PAGE according to the method of Laemmli (26).
Samples were electrophoresed on two different 15 3 20-cm gels, each
with a 4% stacking gel: one using a 7–9.5% gradient (to maximize
separation of the higher molecular weight range proteins), and the
other using a 12.5–15% gradient (for separation of the lower molecular
weight proteins). In addition, human erythroid spectrin (Sigma) was
also electrophoresed on the 7–9.5% gradient gel. Two different molec-
ular weight markers were run alongside these lanes: NOVEX See Blue
Ladder (4–250-kDa range) and Bio-Rad Kaleidoscope Ladder (7.1–208-
kDa range). After electrophoresis, gels were stained with SYPRO or-
ange (1:5,000 dilution) (Bio-Rad) in 10% acetic acid for 45 min to 1.5 h.
Gels were visualized on a VISTA FluorimagerSI using ImageQuant
software (Molecular Dynamics).
Immunoprecipitation—For immunoprecipitation (IP), chromatin-as-
sociated protein extracts from normal human, HeLa, FA-A, and trans-
duced FA-A cells were prepared in 50 mM potassium phosphate, pH 7.0,
1 mM EDTA, 1 mM dithiothreitol, and 40% glycerol. For anti-FANCA IP,
affinity-purified rabbit polyclonal antisera generated from the carboxyl-
terminal region of the FANCA protein, or pre-immune serum, was
bound to protein A-coated agarose beads (Sigma) in binding buffer (25
mM Tris-Cl, pH 7.3, 150 mM NaCl, 1% Triton X-100 plus protease
inhibitor mixture (Roche Molecular Biochemicals)). For anti-a spectrin
IPs, anti-a spectrin (prepared against chicken blood cell membranes,
specific for mammalian nonerythroid a spectrin and chicken a spectrin)
(Chemicon, mAb 1622), or anti-mouse IgG1 (Sigma) (used as a control)
was bound to protein G-coated agarose beads (Sigma) in binding buffer.
These beads were blocked in blocking buffer (4% nonfat dried milk
blocker (Bio-Rad) in TTBS (25 mM Tris-Cl, pH 7.3, 150 mM NaCl, and
0.05% Tween 20)), washed, and resuspended as a 1:3 slurry in binding
buffer. Immunoprecipitation was carried out by mixing 30 ml of this
slurry with 25 mg of chromatin-associated protein extract and an equal
volume of IP buffer (25 mM Tris-Cl, pH 7.3, 125 mM NaCl, 1% Triton
X-100 plus protease inhibitor mixture) overnight at 4 °C. Protein con-
centrations were determined using Bradford reagent (Bio-Rad). The
protein A- or G-agarose bead-bound immune complexes were then
washed three times with IP buffer and resuspended in this buffer. The
IPs and aliquots of chromatin-associated extracts from the cell lines
examined were subjected to SDS-PAGE, using 8–16% gradient gels or
10% gels. After electrophoresis, the proteins were transferred to nitro-
cellulose and immunoblotted.
Immunoblotting—For immunoblotting, chromatin-associated pro-
teins from the nucleus of either normal human lymphoblastoid, HeLa,
FA-A, FA-B, FA-C, FA-D, or transduced FA-A cells, or human erythroid
spectrin (Sigma) were separated on SDS-PAGE, using either 7.5 3
8.5-cm or 15 3 20-cm gels, following the method of Laemmli (26). The
proteins were then transferred to nitrocellulose in transfer buffer (25
mM Tris-Cl, pH 8.3, 192 mM glycine, and 20% (v/v) methanol) at 100
volts for 2 or 2.5 h at 4 °C. The membranes were blocked in blocking
buffer for 1 h at room temperature or overnight at 4 °C and then
incubated in primary antibody in TTBS overnight at 4 °C. After wash-
ing in TTBS, the blots were incubated in secondary antibody (anti-
mouse IgM, anti-mouse IgG, or anti-rabbit IgG) or protein A conjugated
to horseradish peroxidase in 1% nonfat dried milk blocker (Bio-Rad) in
TTBS. The blots were washed further in TTBS and reacted with sub-
strate (Pierce Ultra or Pierce Super chemiluminescent substrate) and
exposed to x-ray film (Pierce). The primary antibodies used were anti-
aSpIIS*, anti-a spectrin, anti-FANCA (carboxyl-terminal), anti-
FANCC (amino-terminal) (generous gift of Dr. Alan D’Andrea, Harvard
Medical School), and anti-topoisomerase II (Oncogene). When blots
were reprobed, they were stripped of IgM using a high salt buffer (20
mM Tris, pH 7.5, 500 mM NaCl, and 0.3% Tween 20) and IgG per the
manufacturer’s instructions (Pierce) and were reblocked before reprob-
ing with primary antibody. Alternatively, blots were incubated with
secondary antibody conjugated to alkaline phosphatase in 1% nonfat
dried milk blocker (Bio-Rad) in TTBS, washed in TTBS and incubated
in 5-bromo-4-chloro-3-indoyl phosphate/nitro blue tetrazolium solution
(Bio-Rad). Images were scanned using a Hewlett-Packard ScanJet 4c/T
scanner and analyzed using ImageQuant (Molecular Dynamics).
RESULTS
A mAb developed against the 230-kDa protein has been used
in its identification. This protein, after separation by gel elec-
trophoresis and identification by Western blot analysis, was
digested with trypsin and analyzed by MALDI-MS. The ration-
ale for using this approach is that it is very sensitive and the
mass spectrum of the peptide mixture, resulting from the en-
zymatic digestion of the protein, provides a fingerprint that can
be specific enough to identify the protein (27).
Using this method, the 230-kDa protein was identified as
human nonerythroid a spectrin (a spectrin II). The calculated
peptide masses obtained from the protein digest were searched
against two different data bases to determine the number of
matched peptides. A ProFound search of the peptides obtained
from the 230-kDa protein digest gave a probability score of
1.0e100 to human a spectrin II with a clean break between this
score and the score of the next nonrelated protein. The percent-
age coverage of the known sequence for this protein was 35%
(i.e. the peptide masses obtained for analysis matched to 35% of
the known protein sequence). This exceeded the minimum per-
centage coverage of 25% set as a criterion for a protein match
by the Keck Facility. A second ProFound search was performed,
after deleting sequences that matched human a spectrin II,
and no additional protein was identified. PeptideSearch
matched the same protein with 33% coverage. This analysis of
the 230-kDa protein was repeated on a second sample obtained
from another HeLa cell chromatin-associated protein extract
with the same result. Because the isoform of the a spectrin we
have identified is unknown, this protein has been designated
aSpIIS* in accordance with proposed nomenclature (17, 28).
Confirmation of the 230-kDa protein as aSpIIS* was made
by Western blot analysis. A mAb against an a spectrin, with
specificity for mammalian nonerythroid a spectrin (Chemicon),
bound to the 230-kDa protein from HeLa chromatin-associated
protein extracts (Fig. 1, lane 1); binding of this mAb to human
erythroid spectrin (a and b chains) (Fig. 1, lane 2) was used as
a control. Similarly, anti-aSpIIS* bound to a spectrin in HeLa
cell extracts and to the a and b chains of erythroid spectrin
(Fig. 1, lane 4). Both anti-a spectrin and anti-aSpIIS* showed
cross-reactivity with a and b spectrin. Using these antibodies,
b spectrin was not detected in the HeLa cell chromatin-associ-
ated protein extracts. Confirmation that both mAbs were bind-
ing to the same protein band was made by analysis of the
respective immunoblots lined up with gold-stained proteins
from a section of the same membrane (data not shown). Fur-
ther confirmation of the location of b spectrin on these gels was
obtained by Western blot analysis using a mAb that principally
recognized erythroid b spectrin (data not shown).
Electrophoretic separation of the proteins in the HeLa cell
chromatin-associated protein extracts showed that aSpIIS* is
not one of the major bands present in these protein extracts
(Fig. 2, A, lane 1 and B). The aSpIIS* band (Fig. 2A, lane 1)
lined up exactly with the a spectrin band from erythroid spec-
trin (Fig. 2A, lane 2), which was run alongside it on the same
gel. The identity of these bands was verified by Western blot
analysis. Both proteins, according to electrophoretic mobility,
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had an apparent molecular mass of approximately 230 kDa,
which agrees with previously reported values (230–240 kDa)
(18, 29) and is lower than the calculated molecular mass of 284
kDa for nonerythroid and 280 kDa for erythroid a spectrin (18,
30).
Immunoblotting showed that there are reduced levels of the
230-kDa protein in chromatin-associated protein extracts from
FA complementation group B (FA-B), C (FA-C), and D (FA-D)
cells (Fig. 3, top panel, lanes 3–5) compared with normal ex-
tracts (Fig. 3, top panel, lane 1) just as there are in the FA-A
extracts (Fig. 3, top panel, lane 2). Thus in at least four FA
complementation groups there is a deficiency in aSpIIS*. In
these studies topoisomerase II was used as an internal control
(Fig. 3, bottom panel).
Levels of aSpIIS* are restored to normal in FA-A cells that
have been corrected with FANCA cDNA (Fig. 4, top panel, lanes
1–3), as previously shown (16), indicating that the FANCA gene
plays a role in the stability or expression of this protein. Sim-
ilar results were obtained when immunoblotting was carried
out using anti-a spectrin (Chemicon). Reduced binding of an-
ti-a spectrin to aSpIIS* in FA-A extracts was restored to nor-
mal in corrected FA-A cells (Fig. 4, second panel, lanes 1–3).
Topoisomerase II was used as an internal control.
To determine whether aSpIIS* interacts with the FANCA
and FANCC proteins, immunoprecipitation studies were car-
ried out. Anti-FANCA immunoprecipitation and immunoblot-
ting with either anti-aSpIIS* or anti-a spectrin demonstrated
that aSpIIS* co-immunoprecipitated with FANCA and FANCC
from HeLa chromatin-associated protein extracts (Fig. 5, lane
1). Preliminary studies indicate that FANCG also immunopre-
cipitated with FANCA and FANCC. None of these proteins
co-immunoprecipitated from FA-A extracts, which lack FANCA
and are deficient in aSpIIS* (Fig. 5, lane 2). In extracts from
corrected FA-A cells, aSpIIS* again co-immunoprecipitated
with FANCA and FANCC (Fig. 5, lane 3) and also FANCG
(preliminary data). These results thus show that aSpIIS*
forms a nuclear complex with these proteins. Faint bands were
detected in the pre-immune precipitations (Fig. 5, lane 4) indi-
cating a slight reactivity of the pre-immune sera with spectrin.
The binding of FANCA and FANCC to aSpIIS* was con-
firmed by anti-a spectrin immunoprecipitation (Fig. 6A, lane
1). Anti-a spectrin was used, even though it may be against a
different isoform than our aSpIIS*, because our anti-aSpIIS*
is of the IgM class and cannot be used effectively in immuno-
precipitations. In FA-A extracts, no FANCA and reduced
amounts of aSpIIS* and FANCC immunoprecipitated (Fig. 6A,
lane 2). This corresponds to no expressed FANCA (Fig. 6B, lane
2) and reduced levels of aSpIIS* (Fig. 4, top panel, lane 2) and
FANCC (Fig. 6B, lane 2) in FA-A nuclei. Reduced levels of
FANCC in FA-A cell nuclei have also been reported by Ya-
FIG. 1. Confirmation of the identity of the 230-kDa protein as
nonerythroid a spectrin. Western blot analysis was carried out on
the binding of anti-a spectrin (Chemicon) (1:8,000 dilution) (lanes 1 and
2) and anti-p230 (lanes 3 and 4) to chromatin-associated proteins from
HeLa cells (lane 1 and 3) or to erythroid spectrin (lanes 2 and 4). The
blot was first probed with anti-p230 and then stripped and reprobed
with anti-a spectrin.
FIG. 2. Electrophoretic separation of the HeLa cell chromatin-
associated protein extracts. The HeLa cell extracts were separated
by SDS-PAGE on a 15 3 20-cm gel and stained with SYPRO orange. A,
a 7–9.5% gradient gel for separation of proteins above 100 kDa. Lane 1,
HeLa cell extract; lane 2, erythroid spectrin. B, a 12.5–15% gradient gel
for separation of proteins below 100 kDa. Asterisks indicate the same
bands on different gels.
FIG. 3. A deficiency in aSpIIS* in FA complementation groups
A, B, C, and D. Binding of anti-aSpIIS* to this protein in chromatin-
associated protein extracts from (top panel) normal human lymphoblas-
toid (lane 1), FA-A (HSC 72) (lane 2), FA-B (HSC 230) (lane 3), FA-D
(HSC 62) (lane 4), and FA-C (HSC 536) (lane 5) cells. The arrow
indicates mAb binding to aSpIIS*. Binding of anti-topoisomerase II to
topoisomerse II in these extracts (indicated by the arrow) was used as
an internal control for protein loading (bottom panel, lanes 1–5).
FIG. 4. The deficiency in aSpIIS* in FA-A cells is restored in
the corrected cells. Western blot analysis was carried out on binding
of anti-a SpIIS* (top panel) and anti-a spectrin (Chemicon) (second
panel) to chromatin-associated proteins from the nuclei of normal hu-
man lymphoblastoid cells (lane 1), FA-A cells (HSC 72) (lane 2), and
FA-A cells transduced with a retroviral vector expressing the FANCA
cDNA (HSC 72–17) (lane 3). This blot was also probed with anti-
topoisomerase II, which was used as a loading control (bottom panel,
lanes 1–3).
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mashita et al. (36). In extracts from corrected FA-A cells,
aSpIIS*, FANCA, and FANCC again co-immunoprecipitated
(Fig. 6A, lane 3). These studies confirm that FANCA and
FANCC form a complex with aSpIIS* in the nucleus and that
normal levels of aSpIIS* and FANCA in the nucleus are im-
portant for complex formation.
DISCUSSION
aSpIIS* has now been identified as associated with a protein
complex that we have isolated from normal human cells and
shown to be involved in repair of DNA interstrand cross-links
(12–15). The exact isoform of this protein is not yet know and is
currently being examined. Isoforms of each spectrin gene, gen-
erated by alternative pre-mRNA splicing, have been shown to
occur (17, 18, 30). The presence of different isoforms in differ-
ent cells and even in the same cell suggests distinct functions
for each (18, 30, 31). Anti-aSpIIS* like anti-a spectrin had
cross-reactivity with b spectrin. This probably indicates a com-
mon epitope that is being recognized by these antibodies. This
is not unusual, because genes for nonerythroid a and b spectrin
encode proteins that are approximately 58–60% identical to
their erythroid counterparts (18, 28, 30, 32), and between non-
erythroid and erythroid a and b spectrin there is also signifi-
cant homology (18, 33).
The reduced levels of aSpIIS* that we observe in FA-A,
FA-B, FA-C, and FA-D cells correlate with the decreased levels
of DNA repair synthesis (i.e. unscheduled DNA synthesis) that
are observed in these cells in response to DNA interstrand
cross-linking agents and with the reduced ability of the protein
complex to incise cross-linked DNA (13, 16). These values are
approximately 25–35% of normal cells (16). Because we have
shown that this protein complex contains a number of the
proteins involved in nucleotide excision repair (i.e. XPR, RPA,
TFIIH, HHR23B, XPG, ERCC1, XPF, and PCNA) (16), it is
possible that a role for aSpIIS* in the repair process is to act as
a scaffold to align these proteins so as to enhance their inter-
actions. This alignment could be particularly important in re-
pair of interstrand cross-links where recombination may be
involved (34, 35). Reduced levels of aSpIIS* in the nucleus
would thus be expected to reduce the efficiency of the repair
process rather than inhibit it altogether, consistent with our
experimental findings.
The FANCA and FANCC proteins have been shown to form
a complex in the nucleus (36, 37). The present results show that
aSpIIS* also forms a complex in the nucleus with these pro-
teins. Because studies suggest that FANCA and FANCC may
not bind directly to each other in the nucleus but that their
interaction may involve another, as yet unknown, protein (36),
it is possible that aSpIIS* is this protein. These finding suggest
that aSpIIS* may act as a scaffold to align or enhance inter-
actions between these two FA proteins, possibly other FA pro-
teins such as FANCG, and proteins involved in DNA repair as
well as in other cellular processes. In addition, because levels of
aSpIIS* are reduced in cells from at least four FA complemen-
tation groups (FA-A, FA-B, FA-C, and FA-D), this suggests that
these FA genes may all be involved in the stability or expres-
sion of this protein. This is further demonstrated by the finding
that in FA-A cells expressing the FANCA cDNA, this deficiency
in aSpIIS* is corrected as is the DNA repair defect (16).
The role of nonerythroid spectrin in the nucleus is not com-
pletely understood. Nonerythroid a-spectrin has been shown to
be associated with the nuclear matrix (38). A number of studies
suggest that the nuclear matrix is important in DNA repair
(39–41). aSpIIS* may link the repair process to the nuclear
matrix. a spectrin has also been shown to interact with a
number of proteins (17, 18) and potentially some of these in-
teractions could occur in the nucleus. For example, a spectrin
contains a calmodulin binding site and has been shown to
associate with this protein (19–21) and it also has a SH3
domain, which interacts with tyrosine kinases (17, 20, 22).
Collectively these proteins, which potentially could bind to
aSpIIS* in the nucleus, have been shown to interact with
proteins involved in DNA synthesis, cell cycle progression,
mitosis, gene expression, and signal transduction (17, 19–22,
42). a spectrin has also been shown to be involved in cell growth
and differentiation (17, 18). A deficiency in aSpIIS* in FA cells
could thus have far reaching consequences due to the number
of systems affected. This could possibly explain some of the
diverse cellular and clinical defects reported in FA, such as cell
cycle defects, aberrant induction of apoptosis, and developmen-
tal abnormalities (1–3). Identification of other FA genes and
their products should help determine how many of the FA
proteins form a complex with aSpIIS* and whether these pro-
teins also play a role in the stability or expression of aSpIIS*.
FIG. 5. Binding of aSpIIS* to the FANCA and FANCC proteins
in the nucleus. Chromatin-associated proteins from HeLa (lanes 1 and
4), FA-A (HSC 72) (lane 2), and FA-A transduced (HSC 72–17) cells
were immunoprecipitated with anti-FANCA (lanes 1–3) or pre-immune
antiserum (lane 4) and immunoblotted with either anti-aSpIIS* (top
panel), anti-a spectrin (second panel), anti-FANCA (third panel), or
anti-FANCC (fourth panel).
FIG. 6. Confirmation of the binding of aSpIIS* to the FANCA
and FANCC proteins by anti-a spectrin immunoprecipitation. A,
chromatin-associated proteins form HeLa (lanes 1 and 4), FA-A (HSC
72) (lane 2), and FA-A transduced (HSC 72–17) cells were immunopre-
cipitated with anti-FANCA (lanes 1–3) or anti-mouse IgG1 (which
served as a control) (lane 4) and immunoblotted with either anti-
aSpIIS* (top panel), anti-a spectrin (second panel), anti-FANCA (third
panel), or anti-FANCC (fourth panel). B, Western blot analysis of bind-
ing of anti-FANCA (top panel) and anti-FANCC (bottom panel) to pro-
teins in chromatin-associated protein extracts from Hela (lane 1), FA-A
(HSC 72) (lane 2), and FA-A transduced (HSC 72–17) cells.
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Elucidation of this relationship may help delineate the function
of these FA proteins in the nucleus, the nature of their inter-
action with aSpIIS*, and their role in the deficiency in aSpIIS*
observed in FA cells.
Acknowledgments—We thank Robert Lockwood for culturing of the
human cell lines and Dr. W. Clark Lambert for critically reviewing the
manuscript.
REFERENCES
1. Glanz, A., and Fraser, F. C. J. (1982) Med. Genet. 19, 412–416
2. Auerbach, A. D., and Allen, R. G. (1991) Cancer Genet. Cytogenet. 51, 1–12
3. Strathdee, C. A., and Buchwald, M. (1992) Am. J. Pediatr. Hematol. Oncol. 14,
177–185
4. Zhen, W., Evans, M. K., Haggerty, C. M., and Bohr, V. A. (1993) Carcinogenesis
14, 919–924
5. Buchwald, M., and Moustacchi, E. (1998) Mutat. Res. 408, 75–90
6. Averbech, D., Papadopoulo, D., and Moustacchi, E. (1988) Cancer Res. 48,
2015–2020
7. Lambert, M. W., Tsongalis, G. J., Lambert, W. C., Hang, B., and Parrish, D. D.
(1997) Biochem. Biophys. Res. Commun. 230, 587–591
8. Lo Ten Foe, J., Rooimans, M. A., Bosnoyan-Collins, L., Alon, N., Wijker, M.,
Parker, L., Lightfoot, J., Carreau, M., Calleu, D. F., Savoia, A., Cheng, N.
C., van Berkel, C. G. M., Strunk, H. P., Gille, J. J. P., Pals, G., Kruyt, F. A.
E., Pronk, J. C., Arwert, F., Buchwald, M., and Joenje, H. (1996) Nat. Genet.
14, 320–323
9. Fanconi anaemia/Breast cancer consortium. (1996) Nat. Genet. 14, 324–328
10. Strathdee, C. A., Gavish, H., Shannon, W. R., and Buchwald, M. (1992) Nature
356, 763–767
11. de Winter, J. P., Waisfisz, Q., Rooimans, M. A., van Berkel, C. G. M.,
Bosnoyan-Collins, L., Alon, N., Carreau, M., Bender, O., Dewuth, I.,
Schindler, D., et al. (1998) Nat. Genet. 20, 281–283
12. Lambert, M. W., Fenkart, D., and Clarke, M. (1988) Mutat. Res. 193, 65–73
13. Lambert, M. W., Tsongalis, G. J., Lambert, W. C., Hang, B., and Parrish, D. D.
Mutat. Res. 273, 57–71
14. Lambert, M. W., Tsongalis, G. J., Lambert, W. C., Hang, B., and Parrish, D. D.
(1997) Biochem. Biophys. Res. Commun. 230, 587–591
15. Lambert, M. W., and Lambert, W. C. (1999) Prog. Nucleic Acids Res. Mol. Biol.
64, 257–309
16. Brois, D. W., McMahon, L. W., Ramos, N. I., Anglin, A. M., Walsh, C. E., and
Lambert, M. W. (1999) Carcinogenesis 20, 1845–1853
17. Winkelmann, J. C., and Forget, B. G. (1993) Blood 81, 3173–3185
18. Goodman, S. R., Zimmer, W. E., Clark, M. B., Zagon, J. S., Barber, J. E., and
Bloom, M. L. (1995) Brain. Res. Bull. 36, 593–606
19. Leto, T. L., Pleasic, S., Forget, B. G., Benz, Jr. E. J., and Marchesi, V. T. (1989)
J. Biol. Chem. 264, 5826–5830
20. Wasenius, V.-M., Saraste, M., Salven, P., Eramaa, M., Holm, L, and Lehto,
V.-P. (1989) J. Cell Biol. 108, 79–93
21. Sri Widada, J., Asselin, J., Colote, S., Ferrag, C., Trave, G., Afshar, M., Haiech,
J., and Liautard, J. P. (1989) J. Mol. Biol. 205, 455–458
22. Ziemnicka-Kotula, D., Xu, J., Gu, H., Potempska, A., Kim, K. S., Jenkins, E. C.,
Trenkner, E., and Kotula, L. (1998) J. Biol. Chem. 273, 13681–13692
23. Fu, K.-L., Thub, P. C., Fujino, T., Digweed, M., Liu, J. M., and Walsh, C. E.
(1998) Hum. Genet. 102, 166–169
24. Hang, B., Yeung, A. T., and Lambert, M. W. (1993) Nucleic Acids Res. 21,
4187–4192
25. Williams, K. R., Samandar, S. M., Stone, K. L., Saylor, M., and Rush, J. (1996)
in The Protein Protocols Handbook (Walker, J. M., ed), pp. 541–555, Hu-
mana Press, Totowa, NJ
26. Laemmli, U. K. (1970) Nature 227, 680–685
27. Cottrell, J. S., and Sutton, C. W. (1996) in Methods in Molecular Biology, Vol.
61: Protein and Peptide Analysis by Mass Spectrometry (Chapman, J. R.,
ed), pp. 67–82, Humana Press, Totowa, NJ
28. Ma, Y., Zimmer, W. E., Riederer, B. M., Bloom, M. L., Barker, J. E., and
Goodman, S. R. (1993) Mol. Brain Res. 18, 87–94
29. Saido, T. C., Yokota, M., Nagao, S., Yamamura, I., Tam, E., Tsuchiya, T.,
Suzuki, K., and Kawashima, S. (1993) J. Biol. Chem. 268, 25239–25343
30. Moon, R. T., and McMahon, A. P. (1990) J. Biol. Chem. 265, 4427–4433
31. Bloch, R. J., and Morrow, J. S. (1989) J. Cell. Biol. 108, 481–493
32. Hu, R.-J., Watanabe, M., and Bennett, V. (1992) J. Biol. Chem. 267,
18715–18723
33. Bennett, V., and Gilligan, D. M. (1993) Annu. Rev. Cell Biol. 9, 27–66
34. Thompson, L. H. (1996) Mutat. Res. 363, 77–88
35. Brookman, K. W., Lamerdin, J. E., Thelen, M. P., Hwang M., Reardon, J. T.,
Sancar, A., Zhou, Z.-Q., Walter, C. A., Parris, C. N., and Thompson, L. H.
(1996) Mol. Cell. Biol. 16, 6553–6562
36. Yamashita, T., Kupfer, G. M. Vaf, D., Suliman, A., Joenje, H., Asano, S., and
D’Andrea, A. D. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13085–13090
37. Kupfer, G. M., Naf, D., Suliman, A., Pulsipher, M., and D’Andrea, A. D. (1997)
Nat. Genet. 17, 487–490
38. Bachs, O., Lanini, L., Serratosa, J., Coll, M. J., Bastos, R., Aligue, R., Rius, E.,
and Carafoli, E. (1990) J. Biol. Chem. 265, 18595–18600
39. Koehler, D. R., and Hanawalt, P. C. (1996) Nucleic Acids Res. 24, 2877–2884
40. Johnston, P. J., MacPhail, S. H., Banath, J. P., and Olive, P. L. (1998) Radiat.
Res. 149, 533–542
41. Balajee, A. S., May, A., and Bohr, V. A. (1998) Mutat. Res. 404, 3–11
42. Birge, R. B., Knudsen, B. S., Besser, D., and Hanafusa, H. (1996) Genes Cells
1, 595–613
a Spectrin II Complexes with Fanconi Anemia Proteins32908
